20. Other financial assets
Other financial assets were as follows:
| Other Financial Assets | [Table 4.54] | |||
|---|---|---|---|---|
| Dec. 31, 2008 | Dec. 31, 2009 | |||
| Total | Of which current | Total | Of which current | |
| € million | € million | € million | € million | |
| Loans and receivables | 633 | 142 | 603 | 95 |
| Available-for-sale financial assets | 288 | 4 | 212 | 14 |
| of which debt instruments | 62 | 3 | 63 | 13 |
| of which equity instruments | 226 | 1 | 149 | 1 |
| Held-to-maturity financial investments | 167 | 57 | 107 | 13 |
| Receivables from forward commodity contracts | 81 | 57 | 36 | 34 |
| Receivables from other derivatives | 635 | 373 | 584 | 210 |
| Receivables under lease agreements | 27 | 1 | 25 | 1 |
| Total | 1,831 | 634 | 1,567 | 367 |
Loans mainly comprised capital of €310 million (2008: €310 million) provided to Bayer-Pensionskasse VVaG (Bayer-Pensionskasse) for its effective initial fund and jouissance right capital of €150 million (2008: €150 million).
In 2009, impairment losses of €1 million (2008: €1 million) were recognized on loans and receivables and an impairment charge of €15 million (2008: €14 million) was recognized on available-for-sale financial assets. Unimpaired other financial assets of €13 million (2008: €0 million) were overdue on the closing date.
Available-for-sale financial assets included equity instruments in the amount of €58 million (2008: €84 million) whose fair value could not be determined from a stock exchange or other market price or by discounting reliably determinable future cash flows. These equity instruments are recognized at amortized cost.
Further information on the accounting for receivables from derivatives is given in Note [30].
Receivables under lease agreements relate to finance leases where Bayer is the lessor and the lessee is the economic owner of the leased assets. These receivables comprised expected lease payments of €30 million (2008: €32 million), including €5 million (2008: €5 million) in interest. Of the expected lease payments, €2 million (2008: €2 million) was due within one year, €28 million (2008: €28 million) within the following four years and €0 million (2008: €2 million) after five years.



Overview
Notes to the Consolidated Financial Statements of the Bayer Group
Bayer Links
Investor Relations


Advanced Search



